Analgesics in New Zealand

Analgesics in New Zealand

  • November 2017 •
  • 20 pages •
  • Report ID: 149691
In 2017 analgesics experienced similar current value growth to 2016. The main story in 2017 was the launch of chewable ibuprofen targeted towards children. Due to the stagnant birth rate, the launch by GlaxoSmithKline Consumer Healthcare New Zealand targeted children (rather than infants); in particular, the peak birth group of babies born over 2007/2008, which are now nearing 10 years old. Over the review period, a number of submissions to get paediatric analgesics switched from pharmacy-only t...

Euromonitor International’s Analgesics in New Zealand report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2012-2016, allowing you to identify the sectors driving growth. Forecasts to 2021 illustrate how the market is set to change.

Product coverage:
Systemic Analgesics, Topical Analgesics/Anaesthetic.

Data coverage:
market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
* Get a detailed picture of the Analgesics market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.

We are very sorry, but an error occurred.
Please contact if the problem remains.

Country=NewZealand Industry=OTC ParentIndustry=LifeSciences Date=201711 Topic=Demand Publisher=EuromonitorInternational Price=1000